TY - JOUR
T1 - Effectiveness of COVID-19 vaccination against COVID-19 specific and all-cause mortality in older Australians
T2 - a population based study
AU - Liu, Bette
AU - Stepien, Sandrine
AU - Dobbins, Timothy
AU - Gidding, Heather
AU - Henry, David
AU - Korda, Rosemary
AU - Mills, Lucas
AU - Pearson, Sallie Anne
AU - Pratt, Nicole
AU - Vajdic, Claire M.
AU - Welsh, Jennifer
AU - Macartney, Kristine
N1 - Publisher Copyright:
© 2023 The Authors
PY - 2023/11
Y1 - 2023/11
N2 - Background: Few studies have examined effectiveness of COVID-19 vaccines against COVID-19 and all-cause mortality across different pandemic periods in 2022. Methods: We used linked whole-of-population data from the 2021 Australian Census, Australian Immunisation Register, death registrations and other national datasets including migration data. Among 3.8 million adults aged 65+ years and >170,000 aged care residents, we used survival analysis to estimate vaccine effectiveness (VE) against COVID-19 specific mortality and all-cause mortality, by vaccine dose and time since receipt, adjusted for age, sex and other factors. We also estimated absolute COVID-19 mortality rates. Findings: From January–May 2022 (Omicron BA.1/2), 3250 COVID-19 deaths occurred; from June–November (Omicron BA.4/5) 3185 COVID-19 deaths occurred. During January–May, VE of a 3rd COVID-19 vaccine dose within 3 months was 93% (95% CI 93–94%) whilst VE of a 2nd dose >6 months since receipt was 34% (26–42%). During June–November, VE of a 4th COVID-19 vaccine dose within 3 months was 84% (82–86%) whilst VE of a 3rd dose >6 months since receipt was 56% (50–62%). VE estimates for aged care residents were similar, but absolute risk reductions were substantially greater. During June–November 2022, for all-cause mortality, VE of a 4th dose within 3 months was 58% (56–59%) whilst VE of a 3rd dose >6 months since receipt was 19% (16–22%). Interpretations: COVID-19 vaccination is highly effective against COVID-19 mortality among older adults although effectiveness wanes with time since the last dose. Our findings emphasise the importance of continuing to administer booster doses, particularly to those at highest risk. Funding: This study was funded by the Health Economics Research Division in the Australian Government Department of Health and Aged Care.
AB - Background: Few studies have examined effectiveness of COVID-19 vaccines against COVID-19 and all-cause mortality across different pandemic periods in 2022. Methods: We used linked whole-of-population data from the 2021 Australian Census, Australian Immunisation Register, death registrations and other national datasets including migration data. Among 3.8 million adults aged 65+ years and >170,000 aged care residents, we used survival analysis to estimate vaccine effectiveness (VE) against COVID-19 specific mortality and all-cause mortality, by vaccine dose and time since receipt, adjusted for age, sex and other factors. We also estimated absolute COVID-19 mortality rates. Findings: From January–May 2022 (Omicron BA.1/2), 3250 COVID-19 deaths occurred; from June–November (Omicron BA.4/5) 3185 COVID-19 deaths occurred. During January–May, VE of a 3rd COVID-19 vaccine dose within 3 months was 93% (95% CI 93–94%) whilst VE of a 2nd dose >6 months since receipt was 34% (26–42%). During June–November, VE of a 4th COVID-19 vaccine dose within 3 months was 84% (82–86%) whilst VE of a 3rd dose >6 months since receipt was 56% (50–62%). VE estimates for aged care residents were similar, but absolute risk reductions were substantially greater. During June–November 2022, for all-cause mortality, VE of a 4th dose within 3 months was 58% (56–59%) whilst VE of a 3rd dose >6 months since receipt was 19% (16–22%). Interpretations: COVID-19 vaccination is highly effective against COVID-19 mortality among older adults although effectiveness wanes with time since the last dose. Our findings emphasise the importance of continuing to administer booster doses, particularly to those at highest risk. Funding: This study was funded by the Health Economics Research Division in the Australian Government Department of Health and Aged Care.
KW - COVID-19
KW - Mortality
KW - Vaccine effectiveness
KW - Waning effectiveness
UR - http://www.scopus.com/inward/record.url?scp=85173517913&partnerID=8YFLogxK
U2 - 10.1016/j.lanwpc.2023.100928
DO - 10.1016/j.lanwpc.2023.100928
M3 - Article
SN - 2666-6065
VL - 40
JO - The Lancet Regional Health - Western Pacific
JF - The Lancet Regional Health - Western Pacific
M1 - 100928
ER -